👤 Anil Kumar Maurya

This study characterizes the expression of fibroblast growth factors (FGFs) and their receptors in the porcine corpus luteum (CL) across distinct stages of the oestrous cycle, and evaluates the regulatory role of FGF2 on angiogenesis, steroidogenesis, and cell survival in vitro. The CL was classified morphologically into four phases: Phase I (days 1-8; corpus haemorrhagicum; ELP), Phase II (days 9-14; highly vascularized CL; MLP), Phase III (day 15 onward; ischemic regression; LLP), and Phase IV (corpus albicans; avascular and regressed; RR). Each phase included 10 biological replicates (n = 10). Quantitative RT-PCR revealed significant upregulation (p < 0.001) of FGF1, FGF2, FGF7, FGFR1, FGFR2, and FGFR4 during early and mid-luteal stages. FGFR3 and FGFR2IIIC showed no significant variation, while FGFR2IIIB was downregulated (p < 0.001) during early/mid-luteal stages and upregulated during luteal regression. FGF10 expression declined significantly (p < 0.001) during regression. Western blotting Densitometry confirmed trends mRNA expression. In-vitro supplementation of FGF2 (1, 10, and 100 ng/ml) during the mid-luteal stage enhanced mRNA expression of angiogenic (vWF), steroidogenic (StAR, CYP11A1, 3β-HSD), and cell survival (PCNA, BAX) markers. StAR, CYP11A1, and 3β-HSD were significantly upregulated (p < 0.001) from 24 to 72 h in a dose-dependent manner. vWF and PCNA showed significant increases at 48 and 72 h, while BAX expression progressively declined (p > 0.001). The 100 ng/ml dose elicited the most pronounced effects. These findings suggest that FGF family members exert autocrine/paracrine effects that support luteal cell proliferation, differentiation, angiogenesis, steroidogenesis, and survival, underscoring their critical role in porcine ovarian physiology. Show less

One hundred participants aged 40-65 with subjective complaints of poor memory were randomized into two groups: 300 mg of LN19184 or placebo, once daily for 120 days. At baseline and days 15, 30, 60, and 120, two neuropsychological batteries, the Rey's Auditory Verbal Learning Test (RAVLT) and the Cambridge Neuropsychological Test (CANTAB), were used to assess cognitive function, and the Athens Insomnia Scale was used to evaluate sleep quality. Serum BDNF levels and safety parameters were also assessed. LN19184 improved each measured RAVLT outcome compared to placebo. Supplementation improved proactive interference ( This pilot trial provides early empirical evidence demonstrating that a novel extract blend of Clinicaltrials.gov, identifier CTRI/2020/08/027368. Show less

Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder influenced by genetic, metabolic, and lifestyle factors. Polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene, notably C677T and A1298C, may increase AD susceptibility through disruptions in one-carbon metabolism and homocysteine accumulation. This study examined the association of MTHFR C677T and A1298C variants with metabolic alterations, cognitive decline, and AD risk. A case-control study was conducted with 120 AD patients and 120 cognitively healthy controls. Cognitive function was assessed using the Hindi Mini-Mental State Examination (HMMSE) and Hindi Mattis Dementia Rating Scale (HMDRS). MRI evaluated white matter hyperintensities and cortical atrophy. Biochemical markers, including homocysteine, folate, and vitamin B12, were measured. Genotyping was performed via TaqMan SNP assays. Functional enrichment and protein-protein interaction analyses were conducted to investigate molecular mechanisms. AD cases demonstrated elevated homocysteine and blood glucose, reduced folate, and impaired cognition. Both MTHFR C677T and A1298C polymorphisms were significantly associated with AD risk under dominant and over-dominant models (ORs 3.41-4.09). Risk-allele carriers exhibited pronounced metabolic alterations. Bioinformatics analyses revealed disruption in one-carbon metabolism, oxidative stress defense, and vascular pathways, with indirect interactions between MTHFR and key AD genes (APP, PSEN1/2, MAPT, APOE, CLU, PICALM, SORL1). MTHFR C677T and A1298C variants contribute to AD susceptibility through metabolic and vascular mechanisms that exacerbate cognitive decline. Integrating genetic, biochemical, and cognitive assessments highlights potential targets for early prevention and therapeutic interventions. Show less

In this study, we developed an economical treatment process for highly acidic effluents from steel rolling mills containing toxic heavy metals. Our method involves a pH-dependent approach using mining waste and hydrated lime. The treatment occurs in two steps: First, metal oxides precipitate at pH 3-3.5 using mining waste, followed by lime precipitation at pH 9-9.5. The process, completed in less than 6 h without heavy machinery, reduces sludge formation by extracting high-purity gypsum, a valuable industrial product. Water quality posttreatment matches local groundwater standards. Compared to conventional methods like common effluent treatment plant (CETP) in Jodhpur, India, our approach reduces operational costs by over 58%. In this study, we also characterized the by-product formed, that is, gypsum using various characterization tools and performed a detailed cost analysis. PRACTITIONER POINTS: A quick, efficient, and economical treatment process for extremely acidic (pH ~ 1) wastewater from steel industries. Stepwise treatment strategy without involving heavy machinery or high manpower. Processed water quality closely resembles groundwater with all the major heavy metals been removed. Sludge quantity reduced by regeneration of pure gypsum (96% purity). Reduced the overall operation cost of effluent treatment by 58%. Show less